Align Technology (NASDAQ:ALGN) Posts Earnings Results, Beats Estimates By $0.32 EPS

Align Technology (NASDAQ:ALGN) announced its earnings results on Wednesday. The medical equipment provider reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.26 by $0.32, FiscalAI reports. The company had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. Align Technology had a return on equity of 15.16% and a net margin of 10.17%.The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter last year, the company earned $2.13 earnings per share.

Here are the key takeaways from Align Technology’s conference call:

• Better-than-expected Q1: Revenues were $1.04B (up 6.2% YoY), clear aligner shipments hit a record 686,000 cases, and non-GAAP gross margin expanded, reflecting operational efficiencies and higher ASPs.
• Broad international and channel momentum: Double-digit volume growth in EMEA, APAC and Latin America, DSOs accounted for ~25% of volumes, iTero active scanner base exceeded 125,000 with over 12M scans in Q1.
• Capital returns and guidance reaffirmed: Management reaffirmed full‑year 2026 guidance (3%–4% revenue growth, mid-single‑digit aligner volume growth) and announced up to $200M more in share repurchases, with $800M still available under the program.
• Near-term demand risks and North America softness: North America showed a modest YoY decline, and management baked prudence into Q2 guidance citing potential patient‑traffic, consumer and freight impacts from the Middle East conflict and adverse FX.
• Cost and revenue-timing headwinds: Operating expenses rose 8.3% YoY driven by legal settlement costs and higher compensation, and deferred revenue declined as the product mix shifts toward zero‑AA configurations that accelerate recognition (improving cash conversion but reducing future deferral-based revenue).

Align Technology Stock Up 0.6%

NASDAQ ALGN opened at $178.40 on Thursday. The company has a market cap of $12.78 billion, a price-to-earnings ratio of 31.52, a price-to-earnings-growth ratio of 2.01 and a beta of 1.81. Align Technology has a twelve month low of $122.00 and a twelve month high of $208.30. The business’s fifty day moving average is $179.29 and its 200 day moving average is $163.92.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on ALGN. Leerink Partners increased their target price on Align Technology from $210.00 to $225.00 and gave the stock an “outperform” rating in a research note on Thursday, February 5th. Barclays upgraded Align Technology from an “equal weight” rating to an “overweight” rating and set a $200.00 target price on the stock in a research note on Tuesday, March 17th. Jefferies Financial Group increased their target price on Align Technology from $155.00 to $185.00 and gave the stock a “hold” rating in a research note on Thursday, February 5th. Citigroup initiated coverage on Align Technology in a research note on Wednesday, April 15th. They set a “buy” rating and a $240.00 target price on the stock. Finally, Piper Sandler increased their price target on Align Technology from $220.00 to $235.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 21st. Eight equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $203.92.

Key Headlines Impacting Align Technology

Here are the key news stories impacting Align Technology this week:

• Positive Sentiment: Q1 earnings beat — EPS of $2.58 topped estimates of $2.26 and revenue of $1.04B beat the $1.02B consensus; revenue was up ~6.2% year-over-year, signaling continued demand for Invisalign and iTero. Reuters: Align Technology beats quarterly estimates, plans $200M buyback
• Positive Sentiment: $200M share repurchase authorized (about 1.6% of shares outstanding) — a capital-return move that typically supports the stock and signals management confidence in valuation. Business Wire: Q1 results and $200M repurchase
• Positive Sentiment: Company reaffirmed fiscal 2026 guidance in its press release, which reduces uncertainty around full-year targets despite some quarter-to-quarter variability. Business Wire: Fiscal 2026 guidance reaffirmed
• Neutral Sentiment: Full Q1 details, slide deck and conference-call transcript are available for deeper review of regional trends, scanner/unit volumes and margin drivers. Useful for modeling next quarters. MarketBeat: Q1 materials and transcript
• Neutral Sentiment: Analyst/industry write-ups note ALGN’s valuation and longer-term potential as a digital dentistry leader; these provide context but are not new catalysts. Zacks: Why ALGN is a strong value stock
• Negative Sentiment: Near-term caution — Q2 revenue guidance was issued as a $1.0B–$1.1B range (versus a ~$1.1B consensus), which could temper upside if revenue prints toward the low end of the range; watch Q2 guide execution and regional trends. MarketBeat: Q1 results and Q2 guidance notes

Align Technology announced that its board has authorized a stock buyback plan on Wednesday, April 29th that permits the company to buyback $200.00 million in outstanding shares. This buyback authorization permits the medical equipment provider to reacquire up to 1.6% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s leadership believes its stock is undervalued.

Insider Transactions at Align Technology

In related news, EVP John Morici sold 7,969 shares of the firm’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $189.31, for a total transaction of $1,508,611.39. Following the completion of the transaction, the executive vice president directly owned 8,237 shares of the company’s stock, valued at $1,559,346.47. This trade represents a 49.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.75% of the stock is currently owned by corporate insiders.

Institutional Trading of Align Technology

Large investors have recently made changes to their positions in the company. Invesco Ltd. boosted its stake in shares of Align Technology by 37.4% in the 3rd quarter. Invesco Ltd. now owns 1,497,535 shares of the medical equipment provider’s stock worth $187,521,000 after buying an additional 407,559 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Align Technology by 72.0% in the 3rd quarter. Bank of America Corp DE now owns 1,353,125 shares of the medical equipment provider’s stock worth $169,438,000 after purchasing an additional 566,488 shares during the period. AQR Capital Management LLC raised its holdings in shares of Align Technology by 65.8% in the 4th quarter. AQR Capital Management LLC now owns 1,196,428 shares of the medical equipment provider’s stock worth $186,822,000 after purchasing an additional 474,756 shares during the period. Jacobs Levy Equity Management Inc. raised its holdings in Align Technology by 30.9% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,005,837 shares of the medical equipment provider’s stock valued at $157,061,000 after acquiring an additional 237,581 shares during the period. Finally, Morgan Stanley raised its holdings in Align Technology by 4.7% during the 4th quarter. Morgan Stanley now owns 944,850 shares of the medical equipment provider’s stock valued at $147,539,000 after acquiring an additional 42,282 shares during the period. 88.43% of the stock is currently owned by institutional investors and hedge funds.

About Align Technology

Align Technology, Inc (NASDAQ: ALGN) pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.

The company’s signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.